Takeda Pharmaceuticals TAK shares are trading higher on Monday after Blackstone signed a definitive agreement to acquire Takeda Consumer Healthcare Company. No financial terms were disclosed.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.3 trillion in 2019. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 70% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
Takeda Pharmaceuticals shares were trading 1.8% higher at $19.19 at the time of publication Monday. The stock has a 52-week high of $20.92 and a 52-week low of $12.43.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.